文献速递白血病MDS 与骨髓增殖性肿瘤

地西他滨、维奈克拉与泊那替尼治疗进展期慢性髓性白血病及费城染色体阳性急性髓系白血病:单臂单中心2期试验

Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial.
PubMed 文献 · Lancet Haematol · 2024-09-17

这项单臂单中心2期试验评估了地西他滨、维奈克拉与第三代BCR::ABL1酪氨酸激酶抑制剂泊那替尼联合方案治疗进展期费城染色体阳性髓系疾病的疗效与安全性。20例患者中复合完全缓解率为50%,常见3-4级非血液学不良事件为发热性中性粒细胞减少、感染和转氨酶升高。作者认为该联合方案安全且显示出有前景的活性,需进一步研究。

要点

  • 20例可评估患者中复合完全缓解率(完全缓解或伴不完全血液学恢复的完全缓解)为50%。
  • 最常见3-4级非血液学不良事件为发热性中性粒细胞减少(40%)、感染(30%)和转氨酶升高(25%)。
  • 8例(40%)患者发生至少一次任何级别心血管事件,3例研究期间死亡均与治疗无关。

核心结论

  • 地西他滨、维奈克拉与泊那替尼联合方案在进展期慢性髓性白血病患者中安全且显示出有前景的活性,包括既往多线治疗或高危特征患者。
  • 作者认为需要进一步研究评估化疗联合维奈克拉为基础、使用更新代BCR::ABL1酪氨酸激酶抑制剂的联合策略。

研究设计与样本

  • 单臂、单中心2期试验,纳入年龄18岁及以上、既往未治疗或复发难治的髓系慢性髓性白血病急变期、慢性髓性白血病加速期或进展期费城染色体阳性急性髓系白血病患者。
  • 患者无论既往治疗线数或既往是否接受泊那替尼均符合条件,ECOG体能状态0-3分。
  • 第1周期诱导:泊那替尼45 mg口服每日1次共7天导入(第1-7天),随后第8-28天联合地西他滨20 mg/m2静脉第8-12天、维奈克拉口服每日递增至最大400 mg第8-28天、泊那替尼45 mg口服每日1次第8-28天。
  • 第2-24周期:地西他滨20 mg/m2静脉第1-5天、维奈克拉口服400 mg第1-21天、泊那替尼口服每日1次第1-28天;巩固周期根据缓解调整泊那替尼剂量:达到完全缓解或伴不完全血液学恢复的完全缓解者减至30 mg每日1次,BCR::ABL1转录本不可测者减至15 mg每日1次。
  • 主要终点为意向治疗人群中完全缓解或伴不完全血液学恢复的完全缓解的复合率,安全性在意向治疗人群中评估;试验注册号NCT04188405,仍在进行中。

主要发现

  • 2020年7月12日至2023年7月8日共治疗20例患者:髓系慢性髓性白血病急变期14例、慢性髓性白血病加速期4例、进展期费城染色体阳性急性髓系白血病2例。
  • 中位年龄43岁(IQR 32-58);男性13例(65%)、女性7例(35%);白人12例(60%)、西班牙裔3例(15%)、黑人4例(20%)、亚裔1例(5%)。
  • 12例(60%)既往接受过2种或以上BCR::ABL1酪氨酸激酶抑制剂,14例(70%)至少有一种高危附加染色体异常或复杂核型。
  • 中位随访时间21.2个月(IQR 14.1-24.2);复合完全缓解率为50%(20例中10例),其中完全缓解1例(5%)、伴不完全血液学恢复的完全缓解9例(45%);另有6例(30%)达到形态学无白血病状态。
  • 最常见3-4级非血液学不良事件为发热性中性粒细胞减少8例(40%)、感染6例(30%)、丙氨酸或天冬氨酸转氨酶升高5例(25%);8例(40%)发生至少一次任何级别心血管事件;3例研究期间死亡,均认为与治疗无关,均死于难治性白血病背景下的感染。

临床怎么用

  • 作者认为地西他滨、维奈克拉与泊那替尼联合方案在进展期慢性髓性白血病中安全且显示出有前景的活性。
  • 作者建议进一步研究评估化疗联合维奈克拉为基础、使用更新代BCR::ABL1酪氨酸激酶抑制剂的联合策略。

局限性

  • 单臂、单中心设计。
  • 样本量小(20例)。
  • 作者指出需要进一步研究评估化疗联合维奈克拉为基础、使用更新代BCR::ABL1酪氨酸激酶抑制剂的联合策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Advanced phase Philadelphia chromosome-positive myeloid disease-consisting of chronic myeloid leukaemia in the myeloid blast phase and in the accelerated phase, and Philadelphia chromosome-positive acute myeloid leukaemia-is associated with poor outcomes. Although previous studies have suggested the benefit of chemotherapy and BCR::ABL1 tyrosine kinase inhibitor combinations, the optimal regimen is uncertain and prospective studies for this rare group of diseases are scant. Preclinical and retrospective clinical data suggest possible synergy between the BCL-2 inhibitor venetoclax and BCR::ABL1 tyrosine kinase inhibitors. We therefore aimed to design a study to evaluate the safety and activity of a novel combination of decitabine, venetoclax, and the third-generation BCR::ABL1 tyrosine kinase inhibitor ponatinib in advanced phase Philadelphia chromosome-positive myeloid diseases. METHODS: For this phase 2 study, patients aged 18 years or older with previously untreated or relapsed or refractory myeloid chronic myeloid leukaemia-blast phase, chronic myeloid leukaemia-accelerated phase, or advanced phase Philadelphia chromosome-positive acute myeloid leukaemia, and an Eastern Cooperative Oncology Group performance status of 0-3 were eligible. Patients were eligible regardless of the number of previous lines of therapy received or previous receipt of ponatinib. Cycle 1 (induction) consisted of a 7-day lead-in of ponatinib 45 mg orally daily (days 1-7), followed by combination therapy with decitabine 20 mg/m2 intravenously on days 8-12, venetoclax orally daily with ramp-up to a maximum dose of 400 mg on days 8-28, and ponatinib 45 mg orally daily on days 8-28. Cycles 2-24 consisted of decitabine 20 mg/m2 intravenously on days 1-5, venetoclax orally 400 mg on days 1-21, and ponatinib orally daily on days 1-28. Response-based dosing of ponatinib was implemented in consolidation cycles, with reduction to 30 mg daily in patients who reached complete remission or complete remission with an incomplete haematological recovery and a reduction to 15 mg daily in patients with undetectable BCR::ABL1 transcripts. The primary endpoint was the composite rate of complete remission or complete remission with incomplete haematological recovery in the intention-to-treat population. Safety was assessed in the intention-to-treat population. This trial was registered with ClinicalTrials.gov (NCT04188405) and is still ongoing. RESULTS: Between July 12, 2020, and July 8, 2023, 20 patients were treated (14 with chronic myeloid leukaemia-blast phase, four with chronic myeloid leukaemia-accelerated phase, and two with advanced phase Philadelphia chromosome-positive acute myeloid leukaemia). The median age was 43 years (IQR 32-58); 13 (65%) patients were male and seven (35%) were female; and 12 (60%) were White, three (15%) were Hispanic, four (20%) were Black, and one (5%) was Asian. 12 (60%) patients had received 2 or more previous BCR::ABL1 tyrosine kinase inhibitors, and 14 (70%) patients had at least one high-risk additional chromosomal abnormality or complex karyotype. The median duration of follow-up was 21·2 months (IQR 14·1-24·2). The complete remission or complete remission with an incomplete haematological recovery rate was 50% (10 of 20 patients); complete remission in one [5%] patient and complete remission with incomplete haematological recovery in nine [45%]). An additional six (30%) patients had a morphologic leukaemia-free state. The most common grade 3-4 non-haematological adverse events were febrile neutropenia in eight (40%) patients, infection in six (30%), and alanine or aspartate transaminase elevation in five (25%). Eight (40%) patients had at least one cardiovascular event of any grade. There were three on-study deaths, none of which was considered related to the study treatment and all from infections in the setting of refractory leukaemia. INTERPRETATION: The combination of decitabine, venetoclax, and ponatinib is safe and shows promising activity in patients with advanced phase chronic myeloid leukaemia, including those with multiple previous therapies or high-risk disease features. Further studies evaluating chemotherapy and venetoclax-based combination strategies using newer-generation BCR::ABL1 tyrosine kinase inhibitors are warranted. FUNDING: Takeda Oncology, the National Institutes of Health, and the National Cancer Institute Cancer Center.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Short NJ, Nguyen D, Jabbour E, et al. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial. Lancet Haematol. 2024. PMID: 39303729. doi:10.1016/S2352-3026(24)00250-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。